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Abstract
Background: Strongyloides stercoralis infects human hosts mainly through skin contact with contaminated soil. The result is
strongyloidiasis, a parasitic disease, with a unique cycle of auto-infection causing a variety of symptoms and signs, with
possible fatality from hyper-infection. Australian Indigenous community members, often living in rural and remote settings,
are exposed to and infected with S. stercoralis. The aim of this review is to determine barriers to control of strongyloidiasis.
The purpose is to contribute to the development of initiatives for prevention, early detection and effective treatment of
strongyloidiasis.
Methodology/Principle Findings: Systematic search reviewing research published 2012 and earlier was conducted.
Research articles discussing aspects of strongyloidiasis, context of infection and overall health in Indigenous Australians
were reviewed. Based on the PRISMA statement, the systematic search of health databases, Academic Search Premier,
Informit, Medline, PubMed, AMED, CINAHL, Health Source Nursing and Academic was conducted. Key search terms included
strongyloidiasis, Indigenous, Australia, health, and community. 340 articles were retrieved with 16 original research articles
published between 1969 and 2006 meeting criteria. Review found barriers to control defined across three key themes, (1)
health status, (2) socioeconomic status, and (3) health care literacy and procedures.
Conclusions/Significance: This study identifies five points of intervention: (1) develop reporting protocols between health
care system and communities; (2) test all Indigenous Australian patients, immunocompromised patients and those exposed
to areas with S. stercoralis; (3) health professionals require detailed information on strongyloidiasis and potential for
exposure to Indigenous Australian people; (4) to establish testing and treatment initiatives within communities; and (5) to
measure and report prevalence rates specific to communities and to act with initiatives based on these results. By defining
barriers to control of strongyloidiasis in Australian Indigenous people, improved outcomes of prevention, treatment of
strongyloidiasis and increased health overall are attainable.
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Introduction
Strongyloidies stercoralis, a nematode parasite, is well docu-
mented as a potentially fatal soil transmitted helminth, described
as a unique and complex human parasite in Speare [1]. S.
stercoralis is a cosmopolitan parasite, but is more prevalent in
tropical regions of the world, including tropical Australia. Rural
and remote regions of Australia, in particular, Queensland,
Northern Territory, Western Australia, north of South Australia
and northern areas of New South Wales, endemic rates [1-5].
Australia’s Indigenous communities have high prevalence of
strongyloidiasis (disease resulting from S. stercoralis) as do
immigrants from other endemic countries, travellers to these
countries and military personnel who have spent time in endemic
regions [6,7]. Soulsby, Hewagama and Brady [8] report four cases
of strongyloidiasis in non-Indigenous people resulting from work-
related exposure presenting at Alice Springs Hospital and by
implication acquired indirectly from Indigenous populations.
Those infected included a teacher at an Indigenous school, a
child care worker, an ex-nurse and a paediatrician. Very high
prevalence rates are reported for Australian Indigenous commu-
nities [3,4,6,7,9,10]. Johnston, Morris, Speare, et al. [7] describe
strongyloidiasis as a clinically important condition in Australia.
Kline, McCarthy, Pearson, et al. [11] discuss major neglected
tropical diseases in Oceania and emphasize strongyloidiasis as an
important infection despite the lack of data on overall prevalence
rates and clinical impact.
Strongyloidiasis in a community is evidence that individual(s) in
that community has been exposed to S. stercoralis from soil
contaminated by human faeces [6]. Infected individuals pass first
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stage larvae in the faeces; these develop on the soil to infective
larvae which penetrate the skin of the next host. After a blood-lung
migration, parasitic adult females (there is no parasitic male) molt
and develop into adult female worms in tunnels in the small
intestinal mucosa [12]. Eggs are then laid in the tunnels, hatch,
and produce first stage larvae in the intestinal lumen. Most of these
pass out in the feces. A small number, however, change to infective
larvae in the gut. These autoinfective larvae penetrate the wall of
the large intestine and re-enter the body. Hence, S. stercoralis is a
very unusual nematode, producing infective larvae not only
externally in the soil, but also internally [12].
The occurrence of the autoinfective larvae is the main reason
strongyloidiasis is such a serious disease [12,13]. Infection is life-
long since adult worms are replaced by young worms and the
infection does not end when the original crop of adults die. Worm
numbers can rise incrementally to produce severe disease, known
as the hyperinfection syndrome. Autoinfective larvae, migrating
from the lumen of the large intestine, can carry enteric bacteria
into the body, resulting in sepsis in any organ. Of patients with the
hyperinfection syndrome, 50% present with a septic event
(pneumonia, septicaemia, meningitis, peritonitis) usually caused
by an enteric bacteria or polymicrobial suite of enteric bacterial
[14]. Complicating this is that S. stercoralis has an immunosup-
pressive effect [15,16]. Hyperinfection occurs mainly, but not
exclusively, in the people who are immunocompromised or
immunodeficient with a high case fatality rate of hyperinfection,
at least 60% [6,7,9,10,13,17,18].
Strongyloidiasis is usually symptomatic [14] but most signs and
symptoms are non-specific. The exception is with larva currens, a
rapidly moving urticarial linear rash that marks the passage of an
autoinfective larvae through the skin [14,19]. This is pathogno-
monic of strongyloidiasis. The other non-specific signs and
symptoms can include gastrointestinal (e.g., abdominal pain,
nausea, diarrhea, weight loss), respiratory (e.g., cough (productive
and non-productive), haemoptysis, cutaneous (e.g., urticara) and
general malaise [7,10,14,20]. Hyperinfective strongyloidiasis, in
addition to the spectrum of acute-infection symptoms, can also
clinically present as paralytic ileus, pulmonary haemorrhage,
pneumonia, meningitis, septicaemia or other bacterial infections
[6,10,14,16,18,20–22].
Diagnostic testing includes serology and faecal examination.
Once diagnosed, strongyloidiasis can be eradicated with specific
anthelmintics, ivermectin being the drug of choice [6,7,12,17].
The recommended treatment for strongyloidiasis has changed
with the development of more effective anthelmintic drugs.
Thiabendazole was the first moderately effective anthelmintic
introduced in the mid-1970s [23,24]. Albendazole, a benzimid-
azole like thiabendazole, was recommended as the treatment of
choice for strongyloidiasis about the mid-1990s [25]. It was
replaced by ivermectin as first line recommended anthelmintic in
the early 2000s [10].
In Australia, ivermectin is not licensed for children ,5 years or
for use in pregnancy [26,27], although there is no evidence of
harm in these groups [10]. Albendazole is used for . 6 months
and ,10 kg to adults, not licensed for use during pregnancy [26–
28]. Fatality from strongyloidiasis most often results from missed
or late diagnosis, inadequate treatment and/or the use of
immunosuppressant drug therapy in high risk groups [6,10,17].
Co-infection of strongyloidiasis with HTLV-1 is associated with
more serious strongyloidiasis and potential resistance to treatment
[10,15]. In addition, HTLV-1 carriers are more likely to develop
T-cell leukaemia when infected with S. stercoralis [29–32].
There are questions about the limited information available
about the prevalence, clinical picture, diagnosis and public health
approaches to manage strongyloidiasis in rural and remote
Indigenous communities in tropical regions of Australia [5,33].
Programs based on the treatment of stool positive individuals have
also been associated with decreases in prevalence [7]. Researchers
suggest that little published evidence of public health approaches
to control strongyloidiasis exists [7,34] and there is a need to
consider mass drug administration in Indigenous Australian
communities with high prevalence of strongyloidiasis [10,11].
This systematic review attempts to answer the questions, what is
the epidemiology of strongyloidiasis in Australian Indigenous
people, and, what, if any, are the mentioned barriers to control?
The aim of this review is to identify research focused on
strongyloidiasis in this specific population and to collect and
analyse available data specific to symptoms, diagnosis and
treatment to determine barriers to control of strongyloidiasis.
For the purpose of this paper, we respectively use the term
Indigenous to represent Australian Aboriginal people and Torres
Strait Islanders.
Methods
The outline and focus of this paper is framed on the concept of a
translational research framework described by Thomson [35]
within the Australian Indigenous HealthInfoNet. This systematic
review was designed as a narrative review of the evidence as a way
to summarise, explain and interpret evidence with thematic
analysis [36].
This systematic review was based on the PRISMA statement, a
tool to summarize accurate, reliable, quality evidence by way of
transparent reporting (Checklist S1) [37,38]. A systematic search
of health databases, Academic Search Premier, Informit, Medline,
PubMed, AMED, CINAHL, Health Source Nursing and
Academic was performed to search for all articles published
2012 and prior were included in the search. Articles were searched
through the online academic search site, Google Scholar and
Author Summary
Strongyloides stercoralis, a nematode parasite, has a well-
documented history of infecting human hosts in tropic
and subtropic regions mainly through skin contact with
inhabited soil. The result is strongyloidiasis, a human
parasitic disease, with a unique cycle of auto-infection
contributing to a variety of symptoms, of which, hyper-
infection causing fatality may occur. In Australia, Indige-
nous community members often located in rural and
remote settings, are exposed to and infected with
strongyloides. Previous researchers report strongyloidiasis
as a recurrent health issue for Indigenous Australians. This
is a systematic review to determine the barriers to control
for this pernicious pathogen. Barriers to control can be
defined across three key themes: (1) health status, (2)
socioeconomic status, and (3) health care literacy and
procedure. By conceptualizing these barriers and address-
ing steps to control as outlined in this study, there is
potential for improvement in prevention and treatment
outcomes of strongyloidiasis and subsequently, overall
health for Australian Indigenous people. This study
contributes to furthering prevention and treatment of
strongyloidiasis, increasing exposure to the issue of
strongyloidiasis in Australian Indigenous people. It is the
intent of this paper to express the need to have continued
research and further health policy directed specifically to
eradicate strongyloidiasis in Australian Indigenous com-
munities.
Strongyloidiasis: Barriers to Control for Australian Indigenous People
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internet searches for websites containing information about
strongyloidiasis. Key search terms included strongyloidiasis,
Indigenous, Australia, health, and community with search strategy
developed to access the broadest range of articles about
strongyloidiasis are presented in Table 1. Reference lists of
original articles, review articles, grey literature and websites were
searched for potential articles to review for inclusion. Language
restrictions were not imposed.
To meet inclusion criteria, original qualitative or quantitative
research articles contained content addressing one or more of the
following: symptoms, diagnosis, treatment, and barriers to control
of strongyloidiasis. The location of the studies had to be Australia
and include Australian Indigenous people. Exclusion criteria
included, review articles and non-peer reviewed literature, original
research articles with animal only studies, pharmaceutical therapy
only studies and studies not differentiating S. stercoralis or
strongyloidiasis from amongst other parasites or parasitic infec-
tions.
Based on these selection criteria, articles were reviewed in two
stages. First stage, article titles and abstracts were screened to meet
the requirements of strongyloidiasis as topic, Australian location
and inclusion of Indigenous Australians. Second stage, articles
were read as full text. Articles meeting final criteria were included
in the study. Figure 1 represents the overall article search
outcome.
From the original research questions, (1) what is the epidemi-
ology of strongyloidiasis in Australian Indigenous people? and (2)
what, if any, are the mentioned barriers to control? Description of
studies was collected and a thematic analysis conducted [36]. Key
data extracted were: purpose of study, study design, participant
description, symptoms, diagnosis, treatment, barriers to control,
and author’s conclusions. Articles were presented in a database
with publisher details and summarized key data. The categories of
symptoms, diagnosis, treatment and barriers to control were
further assessed and coded using thematic analysis to determine
recurring items in each. Symptoms were defined as manifestations
of strongyloidiasis and included symptoms and signs due to
strongyloidiasis and other existing concurrent conditions. Diagno-
sis was defined medical diagnoses including health status, tests
performed and results.
Assessment of treatment of strongyloidiasis was based on the
recommended therapy at the time of publication and defined as
details on therapy provided and the comments on outcomes.
Barriers to control were defined as a medical context, symptom
and/or condition, or social determinant (derived from categories
of symptoms, diagnosis, treatment and each authors’ summary and
conclusions) that inhibited overall health and/or recovery from
strongyloidiasis of the individual(s). Once the barriers to control
items were documented, they were then coded into barrier themes
and health level. Detailing each barrier and the associating theme
and level supports the translational knowledge concept by assisting
to identify the relevant stakeholders [39].
Results
Figure 1 provides an overview of the literature search results.
340 articles were retrieved with a total of 16 articles, published
Table 1. Search strategy.
Number Keywords
1 Strongyloidiasis or strongyloides
2 Strongyloidiasis or strongyloides and Australia
3 Strongyloidiasis or strongyloides and Australia and Aboriginal or Indigenous
4 Strongyloid* and Australia
5 Strongyloid* and Indigenous
6 Strongyloid* and Indig*
7 Strongyloid* and Aborig* or Abor*
8 parasite infe* and Australia and Abor*
9 para* infe* and Australia and Abor*
10 para* infe* and Australia and Indig*
11 strongyloid* and community
12 strongyloid* and health
13 parasite and infe* and Australia and indig*
14 gastro* infe* and Australia and abor*
15 pedia* and Australia and abor*
16 infectious disease and Australia and abor*
17 11 and 4 or 5 or 6 or 7
18 12 and 4 or 5 or 6 or 7
19 10 and 16 and 5 or 6 or 7
20 1 and 16
21 5 or 6 and 15
22 10 and 11
23 10 and 12
*asterisks added to root word to find all forms of word during library search.
doi:10.1371/journal.pntd.0003141.t001
Strongyloidiasis: Barriers to Control for Australian Indigenous People
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between 1969 and 2006, eligible for the systematic review and are
summarized in Table 2. Eleven eligible articles were from elec-
tronic library databases. Google Scholar revealed two additional
eligible articles. The reference lists reviewed from published
articles, grey literature and internet websites reporting on
strongyloidiasis infections of Indigenous people of Australia
Figure 1. Flow diagram represents systematic review search based on the PRISMA statement reporting guidelines for systematic
reviews and meta-analyses [38].
doi:10.1371/journal.pntd.0003141.g001
Strongyloidiasis: Barriers to Control for Australian Indigenous People
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revealed three eligible articles. Study design included case studies,
retrospective and prospective comparison and non-comparison
studies. Participant numbers ranged from 1 to 683. Indigenous
Australian children were reported in 12/16 studies, of those 8/12
reported children only. Indigenous Australian adults were
reported in 7/16 studies, of which 4/7 reported adult only.
Thirteen studies were conducted in hospital and four in
Indigenous communities. Eleven studies examined strongyloidiasis
only with the remaining discussing the parasitic infection in the
context of other infections [40,41] or while examining gastroin-
testinal issues [42–44].The 16 papers included 2537 Indigenous
participants and 272 non-Indigenous participants.
Eleven papers described manifestations of strongyloidiasis,
including symptoms and signs due to strongyloidiasis as well as
other concurrent conditions (Table 3). Studies noted strongyloidi-
asis symptoms such as diarrhoea, malnutrition and anorexia,
abdominal pain, abdominal distension, anemia, septicaemia, and
fever. Other concurrent conditions including Type 2 Diabetes,
Lupus, Chronic Liver Disease and Chronic Lung Disease,
Alcoholism, Pneumonia, Bronchitis, COPD, Acute Rheumatic
Fever, Acute Renal Failure and/or general gastrointestinal, cardiac
and respiratory problems were reported. Gunzburg, Gracey, Burke,
et al. [43] reported only diarrheal symptoms as this was the scope of
the study. Page, Dempsey, and McCarthy [28] and Prociv & Luke
[5], although studying strongyloidiasis specifically, did not focus on
symptomology. Four studies [4,15,40,42] did not discuss sympto-
mology due to the aim of the study.
All sixteen studies provided data on diagnosis of strongyloidiasis
determined by one or more tests (Table 4). Nine studies performed
purposeful testing [4,5,21,28,40–43]. Five studies reported stron-
gyloidiasis had been diagnosed when not suspected
[15,22,42,45,46].
Articles were reviewed for the adequacy of treatment noting that
recommended therapy has changed with time (Table 5). Eight
Table 2. Summary of publications with original research on strongyloidiasis in Australian Indigenous people*.
Study Purpose of Study Study Location participants+ Study Design
[4] To investigate the biomedical consequences of lifestyle
changes among communities in order to help people
understand changes and to cope with them.
Arhhem Land, Northern
Territory
403 Iac Cross-sectional and
longitudinal
[5] To report prevalence and distribution of infections
with S. stercoralis in communities.
Remote communities,
Queensland
122 Ic Retrospective
[21] To present the case of one adult with 10 episodes of
meningitis due to strongyloidiasis.
Fitzroy Crossing, Western
Australia
1 Ia Retrospective case
[22] To report a case study of a child that demonstrates
how clinically unsuspected strongyloidiasis progresses
to hyperinfection after increase in immunosuppression
medication.
Adelaide Childrens Hospital 1 Ic Case
[16] To describe a case of hyperinfection. Royal Darwin Hospital 1 Ia Case
[28] To explore the utility of antibody tests for confirming
cure of strongyldoidiasis in endemic population.
Arnhem land, Northern
Territory
508 Iac Case control
[15] To determine whether complicated strongyloidiasis
occurs in association with HTLV-1 infection.
Alice Springs Hospital 18 Iac Retrospective case
[41] To compare infection-related mortality rates and
pathogens associated for Indigenous and
non-Indigenous adults.
Alice Springs Hospital 351 Ia; 162 Na Retrospective comparison
[40] To compare bloodstream infection rates, pathogens
and mortality among Indigenous and non-Indigenous
adults.
Alice Springs Hospital 614 Ia; 69 Na Retrospective comparison
[42] To report biopsy findings using histological assessment
and examination under dissecting microscope in
intestinal mucosal biopsies from children.
Royal Alexandra Hospital
for children
30 Ic Prospective comparison
[43] To indicate the extent or severity of diarrheal disease
in children in communities.
Kimberley region, Northern
Territory
100 Ic Prospective
[44] To show that the severity of diarrheal disease in
children as a consequence of underlying small
intestinal mucosal damage.
Royal Darwin Hospital,
Northern Territory
339 Ic; 36 Nc Prospective comparison
[45] To describe clinical presentation, diagnosis and
management of strongyloidiasis and to identify
predisposing factors.
Townsville General Hospital 9 Iac; 5 Nac Retrospective
[46] To describe strongyloidiasis in children. Darwin Hospital 8 Ic Case
[50] To describe clinical and laboratory features of
strongyloidiasis.
Royal Darwin Hospital 64 Iac; 4 Nac Retrospective
[51] To present the case of an infant with meningitis
and who subsequently developed complete
small-intestinal obstruction.
Royal Alexandra Hospital
for Children
1 Ic Case
+a =Adult(s); c = child(ren), ac = adult(s) and child(ren), I = Indigenous; N = non-Indigenous;
*For the purpose of this paper, we respectively use the term Indigenous to represent Australian Aboriginal people and Torres Strait Islanders.
doi:10.1371/journal.pntd.0003141.t002
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articles discussed the use of one or a combination of albendazole,
thiabendazole and ivermectin. Three articles described a subgroup
of patients receiving no therapy [28,42,45] and one article
mentioned the use of pyrantel only for strongyloidiasis [5]. Pyrantel
is ineffective against S. stercoralis [47]. In two articles, prednisolone
or prednisone, a treatment which suppresses the immune system
and as a result can increase the severity of strongyloidiasis, was
administered to patients. Walker-Smith [42] discussed diagnoses of
giardiasis and strongyloidiasis in children and provided no data on
treatment. Einsiedel & Fernandes [15] detailed treatment therapies
across four case studies, of which, only one case received correct
strongyloidiasis treatment with ivermectin. Overall, adequate
treatment was documented in publications in only 5.2% of cases.
Barriers to control of strongyloidiasis were summarized in terms
of item, theme and health access level (Table 6). Three barriers
themes emerged as items contributing to adequate management of
strongyloidiasis: (1) health status; (2) socioeconomic status; (3)
health care literacy and procedures. Theme 1, health status was
defined patients’ health prior to and at the time of diagnosis of
strongyloidiasis. This included concurrent infections (e.g., menin-
gitis, pneumonia), concurrent chronic health conditions (e.g.,
Lupus, Chronic Liver Disease, Chronic Lung Disease, Acute
Rheumatic Fever, HTLV-1, Hepatitis B, alcoholism, immuno-
compromised, immunosuppressed) and the phenomenon of
strongyloidiasis (e.g., re-infection, hyperinfection, at times asymp-
tomatic, chronic diarrhoea, septicaemia). Theme 2, socioeconomic
status included living conditions, racial disparities, communication
(e.g., interaction between community, patients, health profession-
als/institutions).Theme 3, health care literacy and procedures
involved barriers that influence the diagnosis and treatment
outcomes (e.g., delayed diagnosis, difficult to detect, failure to
recognize symptoms, inadequate knowledge/treatment/treatment
dose, serology test cut off, lack of communication, lack of
screening, lack of follow-up, treatment non-compliance).
Table 3. Manifestations of strongyloidiasis in Indigenous Australian patients*.
Study Participant details + Other condition Symptoms/signs due to strongyloidiasis
[4] 403: 10 yr and older hepatitis B not listed
[5] 122: under 15 yr not listed not listed
[15] 513: 351 Ind; 162 Non not listed not listed
[16] 1 female 18 yr Grade-IV lupus glomerulonephritis (LG) with nephrotic
syndrome, hypertension, febrile neutropenia, chronic
gastric erosions, non-insulin dependent diabetes, poor
cardiovascular and respiratory function
diarrhea, abdominal pain, anorexia
[21] 1 male adult recurring meningitis, alcoholism E. coli septicaemia
[22] 1 female 12 yr Systemic lupus erythematosus, paralytic ileus,
candidiasis, pneumonia
anemia, headache, back pain, fever, confusion,
bacterial septicaemia
[28] 508: 13 yr and older not listed not listed
[40] 614 Ind; 69 Non: under 15 yr not listed not listed
[41] 18 Case series (C) (4 detailed):
C1 female 39 yr; C2 male 29 yr;
C3 male 32 yr; C4 male 41 yr
C1 chronic liver disease, alcoholism, shoulder pain,
epigastric pain, cachectic; C2 peripheral neuropathy,
chronic liver disease, alcoholism, HTLV-1, hepatitis B,
pleuritic chest pain, productive cough, dyspnea; C3
chronic liver disease, alcoholism, bilateral crackles,
wheeze, dyspnea, hypotensive; C4 Type 2 diabetes,
chronic liver disease, alcoholism, hypotensive, crackles,
wheeze, acute renal failure, intravascular coagulopathy
C1 abdominal pain, severe pruritus, diarrhea,
faecel incontinence; C2 abdominal pain,
diarrhoea; vomiting, septic shock; C3 abdominal
pain, pruritus, diarrhea; C4 Fever, diarrhea,
abdominal pain
[42] 3: 1–5 yr not listed partial villous atrophy of third degree
[43] 100: 0–5 yr not listed Diarrhea
[44] 338 Ind; 37 Non: children hypokalemia; cryptosporidium diarrhoea; malnutrition
[45] 9 Case series: C1 17mos;C2
42 yr; C3 49 yr; C4 11yr; C5
7mo; C6 17 yr; C7 30 yr; C8 1
yr; C9 26 yr
C1 croup; C2 alcoholism, COPD, trichuriasis; C3 no
details; C4 nil; C5 bronchitis, cryptosporidiosis; C6
alcoholism, trichuriasis; C7 systemic lupus
erythematosus, alcoholism, giardiasis; C8 Giardiasis;
C9 Alcoholism, trichuriasis, toxic epidermal
necrolysis, allergies
C1 diarrhoea, rash; C2 abdominal pain; C3
no details; C4 diarrhoea; C5 diarrhoea; C6
abdominal pain, diarrhea, nausea, vomiting/C7
pruritus, death; C8 diarrhoea, vomiting, rash; C9
diarrhoea, septicaemia, recurrent infections
[46] 3 Case series: C1 1 yr; C2
2 yr; C3 4 yr
C1 anaemia; C2 bronchitis, otitis media; C3 acute
rheumatic fever
C1 diarrhoea, failure to thrive, hypokalemia,
hypernatremia, partial intestinal obstruction;
C2 gastroenteritis, hypokalemia, partial intestinal
obstruction; C3 gastroenteritis, intestinal
obstruction
[50] 68: 64 Ind; 3 Non Alcoholism, scabies (and ‘‘other’’ parasites),
pulmonary disease, congestive cardiac failure
anaemia, diarrhea, gastrointestinal symptoms,
malnutrition
[51] 1 female 6mo Pneumonia, H. influenza, meningitis Intestinal obstruction with granulomata around
larvae, vomiting, abdominal distention
Total 2537 Ind; 272 Non
+Participant details: Indigenous Australian unless otherwise specified, Ind = Indigenous, Non =non Indigenous.
*For the purpose of this paper, we respectively use the term Indigenous to represent Australian Aboriginal people and Torres Strait Islanders.
doi:10.1371/journal.pntd.0003141.t003
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Einsiedel & Fernandes [15] had the largest number of symptoms
and signs and other conditions associated with barriers to control
of strongyloidiasis. The top four barriers listed most often
(determined by the most barriers per article, total of 4) were
delayed diagnosis, inadequate treatment, living conditions and
malnutrition. Barriers to control are located across all four health
access levels: (1) Individual; (2) Public/Community; (3) Organiza-
tion; and (4) Healthcare system.
Discussion
This study reviewed original articles on strongyloidiasis in
Indigenous Australian people. Articles were analyzed for symp-
toms, diagnosis and treatment and barriers to control of
Strongyloidiasis. Overall outcomes are presented as symptomology,
diagnosis and treatment protocols, community research and action
and addressing barriers to control.
Symptomology
The broad spectrum of symptoms, as represented in manifes-
tations of strongyloidiasis in Table 3, illustrates the complex
nature of Strongyloidiasis that is so often misdiagnosed. Many of
these manifestations, such as diarrhoea, stomach pain, malnutri-
tion, dehydration and vomiting are common to many illnesses and
diseases. As described by researchers [6,15,16,20,43,45,46],
strongyloidiasis can present many varying symptoms or be
asymptomatic [43,46]. It is important to recognize that strongy-
loidiasis can potentially exist for years presenting often with non-
specific symptoms and signs (e.g., diarrhoea) as well as at times
with periods without symptoms.
Hyperinfection. Einsiedel and Fernandes [15], Byard,
Bourne, Matthews et al., [22] and Potter, Stephens and De
Keulenaer [16] report specific cases of hyperinfection. Of these 4
specific cases fatality occurred in two of these studies [15,22].
Results support previous research indicating that cases of
hyperinfection and fatality may be prevented the earlier strongy-
loidiasis is diagnosed as undetected strongyloidiasis over longer
periods lead to this outcome. Adams, Page and Speare [6] and
Speare and Durrheim [12] report attention must be paid to those
who are immunocompromised and, in all cases, steroid medication
should not be administered until a diagnosis of strongyloidiasis is
confirmed or ruled out. Early diagnosis increases probability of
recovery. The possibility of hyperinfection or disseminated
strongyloidiasis in immunocompromised patients, particularly in
endemic areas, needs consideration [48]. The current protocol in
place is to give the first dose of ivermectin when strongyloidiasis is
suspected (i.e., when blood or faeces is taken) and then to give
follow-up doses when test are positive. For those from a high
prevalence area taking an immunosuppressive treatment (and until
finished) are to continue with follow up strongyloidiais treatment
every three months [26,27,49].
Diagnosis and treatment protocols
Delayed diagnosis, inadequate knowledge/treatment/treatment
dose, lack of communication and lack of follow up by health
professionals were described as particular issues in the majority of
studies [5,15,16,22,29,40,44,45,50,51]. Infection should be sus-
pected in every person with unexplained abdominal pain,
diarrhoea, cutaneous symptoms or eosinophilia and the laboratory
alerted of a provisional diagnosis [45]. Testing for strongyloidiasis
is particularly important for patients from populations in S.
stercoralis endemic areas. Rural and remote Indigenous commu-
nities (more specifically northern Australia) and including immu-
nocompromised patients are at particular risk for hyperinfecion
before administering immunosuppressive medication [22]. Proto-
col including clinical screening index, stool microscopy and
culture, full blood count, immunoglobulin levels, and serological
testing is recommended [22].
Majority of studies reported Indigenous Australian children
with strongyloidiasis suggesting a diagnosis of strongyloidiasis
should be considered when Indigenous children presenting with
even non-suspecting general gastro-intestinal symptoms. Mucosal
damage in Indigenous Australian children is possibly a result of
damage produced by repeated episodes of gastroenteritis and/or
parasitic infection, including strongyloidiasis [42]. Reduction in
Table 4. Tests performed to diagnosis patients’ condition not necessarily specifically related to strongyloidiasis diagnosis.
Study Tests Performed
[4] Blood; Stool
[5] Stool
[15] Abdominal scan; Chest x-ray; Serology; Stool
[16] Abdominal scan; Brain scan; Chest x-ray; Blood; Stool
[21] Cerebral spinal fluid protein level/neutrophil count; CT scan; Blood; Stool
[22] Cytology; Gastric aspirate; Lung biopsy
[28] Serology
[40] Blood
[41] Serology
[42] Intestinal biopsy
[43] Stool
[44] Blood; Stool
[45] Stool
[46] Abdominal x-ray; Chest x-ray; Gastric aspirate
[50] Stool
[51] Abdominal x-ray; Abdominal x-ray/barium enema; Gastric aspirate; Laparotomy; Lumbar puncture; Stool
doi:10.1371/journal.pntd.0003141.t004
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the frequency of gastroenteritis and parasitic infection in
Indigenous children should greatly reduce incidence of small
intestinal mucosal damage [42]. Working to eradicate or reduce
strongyloidiasis infection in children with early detection and
immediate treatment could decrease strongyloidiasis and mucosal
damage. Given the challenges of diagnosing infection, standard-
izing treatment in communities for an extended period could
potentially decrease infections rates [5].
Lack of follow-up. There was a repeated lack of follow-up
within and across cases of strongyloidiasis [15,45,50]. It is quite
possible that patients treated for stronygloidiasis may continue to
carry the infection as has been presented in cases with people
suffering from strongyloidiasis infection for years after initial
exposure [16,21]. This is problematic for a number of reasons.
There is increased health risk to the patient as a result of continued
infection including hyperinfection and fatality. The lack of
awareness of continued infection in patient leads to increased risk
for infection in the patients’ community and decreases awareness by
health professionals and community for need to eradicate the
infestation within community and finally. This leads to inadequate
reporting of strongyloidiasis in communities and under-representa-
tion of strongyloidiasis prevalence rates. Diagnosis and treatment of
strongyloidiasis is challenging and requires specific knowledge. This
knowledge must be acquired and maintained by health professionals
in Australia and in particular, when assisting Indigenous Australian
community members [6]. Assistance begins not only at the point of
care in the hospital but also at the community level.
Treatment. The low rate of adequate treatment documented in
the cases reported in the literature is of concern (Table 5). Einsiedel
and Fernandes [15] highlighted that many (14/18) Indigenous
patients in Central Australia received no treatment. Our reassessment
of the four patients that did receive treatment in their series showed
that all regimes were inadequate. Serological diagnosis means that
confirmation of strongyloidiasis is usually delayed and for patients in
remote areas of Australia this delay may have extended to several
weeks [12]. As a result some clinicians used the approach that if a
sample was collected for S. stercoralis serology the patient should
receive the first dose of ivermectin [48]. Subsequent management
would then depend on the serological result.
Community research and action
Parasitic diseases have significant health risk and morbidity for
Australian Indigenous people [11,20]. Rural and remote commu-
nities are the most affected [3,18]; mainly in children; and those
Table 5. Assessment of whether cases reported in papers were adequately treated according to the recommended anthelmintic
for that time.
Study Anthelmintic used Comment Total Evidence* %
[4] No comment on treatment Total 411 (positive: 60% serology; 41% faeces) 246 0 0
[5] Pyrantel used as a routine de-wormer in Queensland
Aboriginal health program – does not treat
strongyloidiasis; thiabendazole given for strongyloidiasis
(sometimes) but usually for 2 days not 3; so arguably
none received adequate treatment
Multiple cases in children (,16yr) – 1971–1991:
thiabendazole used, but probably not for most
cases; comment made that children often
refused drug due to unpleasant side effects
632 0 0
[15] Albendazole = 1 (single dose); Ivermectin = 3;
No treatment = 14
In 18 patients treatment was inadequate since
14 no treatment; 1 single dose albendazole;
3 single dose of ivermectin. (15/18 patients died)
18 0 0
[16] Albendazole and ivermectin (sequence) Treatment successful 1 1 100
[21] No comment on therapy 1 adult male 1 0 0
[22] No comment Indigenous female child with hyperinfection 1 0 0
[28] Albendazole single = 10 (inadequate); Albendazole
multiple = 10 (adequate); Ivermectin single = 19
(inadequate); Ivermectin multiple = 42 (adequate)
Was a critical paper in that demonstrated
albendazole was less effective than ivermectin;
hence, both albendazole and ivermectin
considered adequate
79 52 66
[40] No comment Study on blood stream infection 73 0 0
[41] No comment Study on deaths in hospitalized patients 2 0 0
[42] None described Not stated how many children had S. stercoralis
[43] No comment on treatment 12 children with S. stercoralis in faeces 12 0 0
[44] No comment Study on diarrhoea in children admitted
to Royal Darwin Hospital
23 0 0
[45] Thiabendazole Of 6 adults, 4 adequately treated; Of 3
children, 2 adequately treated
9 6 67
[46] Thiabendazole Case 1: 1 course of unstated length;
eosinophilia on discharge; Case 2: No details;
eosinophilia on discharge; Case 3: No details
3 0 0
[50] Thiabendazole Details for Indigenous patients not given;
comment made that 57% of all (not just
Indigenous) patients received adequate
treatment
64 57 (54–61)
[51] Thiabendazole multiple doses and courses No larvae found at end and eosinophil
count normal
1 1 100
Total 1165 60 5.2
*Evidence of adequate treatment.
doi:10.1371/journal.pntd.0003141.t005
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immunocompromised with a number of cases of fatality reported
[15,22,40,41]. Studies in 2002 and 2005 report there are limited
published examples of community interventions in Australia to
control strongyloidiasis [7,52]. Johnston, Morris, Speare, et al. [7]
found no evidence of studies examining roles of environmental
interventions and expressed the need to do so. The need for
initiatives for housing and sanitation are imperative [15]. Issues of
environmental health must be addressed concurrently with health
service initiatives to develop long term and sustainable improve-
ments in control of infectious parasitic and non-parasitic diseases in
rural and remote Indigenous communities in Australia [10,11,20].
There may be increased risks associated with a casual approach to
management and may be significantly higher for Indigenous
Australian people living in HTLV-1 endemic Central Australia
[10,40]. Einsiedel and Woodman [40] further state the risk of
strongyloidiasis in Indigenous communities and HTLV-1 infection
may further predispose people to complicated strongyloidiasis.
Addressing barriers to control
Steps to address the barriers to control should include: (1)
development of S. stercoralis and strongyloidiasis reporting
protocols across health care system and communities (e.g.,
consistent case study reporting methods, documentation of current
infection sites) [6,40]; (2) testing all Indigenous Australian patients,
immunocompromised patients and those exposed to or living in
areas of strongyloidiasis (e.g., rural/remote communities) present-
ing with gastrointestinal or respiratory symptoms (take particular
notice of individuals from these groups with repeated visits to
hospital) [7,15,16,48]; (3) requirement of health professionals to
have detailed information and education regarding strongyloidiasis
and the potential for exposure in Indigenous Australian commu-
nities (e.g., understanding of the expanse of symptoms and
potential for asymptomology, difficulty in diagnosis, need for
variety of tests and retesting, accurate follow-up to confirm patient
cleared of infection) [5,15,21,42]; (4) establishment of testing and
treatment initiatives in the community (e.g., over extended periods
and periodically and treat symptomatic and asymptomatic
strongyloidiasis carriers) [6,10,12,15,45]; (5) measure and report
prevalence specific to Indigenous Australian communities and to
act with initiatives based on these results [6,12,40].
Limitations. Studies analyzed for this review had an overall
lack of detailed information on prevalence rates, diagnosis and
treatment outcomes. Repeated lack of follow-up made it difficult
to determine outcomes for those reported infected with strongy-
loidiasis in studies. In addition, a number of articles [5,15,50]
conducted retrospective studies of hospital records with reported
missing data, missing records and inconsistent reports. Case
studies did not have a consistent reporting protocol to facilitate
analysis within and across cases. It was unfortunate that a number
of studies had to be excluded from this review as they had gathered
overall parasite infection data in Indigenous Australian commu-
nities but had not further represented data by parasite (e.g.,
hookworm, S. stercoralis). This data would have been potentially
valuable for increasing both the evidence and support to further
define strongyloidiasis a problem for Indigenous Australians.
Conclusions. If barriers are managed, current research and
the health care system can report accurately and provide the data
required to support initiatives to eradicate strongyloidiasis in
Indigenous Australian communities. Addressing these barriers
would support conclusions of researchers that health education
and public health interventions and guidelines for mass treatment
with follow-up for effective treatment are essential [6,10,11]. As
Einsiedel and Woodman [40] state sustainable improvements
require a coordinated approach based on dialogue, cultural
understanding and development of locally specific solutions by
Indigenous people themselves. This comprehensive focus with
Indigenous Australian people and their communities on strongy-
loidiasis is imperative. Community initiatives to eradicate endemic
parasite infection such as hookworm have had success and there is
potential to do the same with S. stercoralis [10].
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